These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 25211849)

  • 1. Big Pharma's small wonder.
    Fry E
    Fortune; 2014 Jun; 169(8):178-84, 186. PubMed ID: 25211849
    [No Abstract]   [Full Text] [Related]  

  • 2. Purdue Pharma's "predatory and deceptive" advertiser Publicis pays $350m to US states.
    Dyer O
    BMJ; 2024 Feb; 384():q316. PubMed ID: 38320781
    [No Abstract]   [Full Text] [Related]  

  • 3. Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review.
    Geynisman DM; Chien CR; Smieliauskas F; Shen C; Shih YC
    Hum Vaccin Immunother; 2014; 10(11):3415-24. PubMed ID: 25483656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab.
    Gebhardt C; Sevko A; Jiang H; Lichtenberger R; Reith M; Tarnanidis K; Holland-Letz T; Umansky L; Beckhove P; Sucker A; Schadendorf D; Utikal J; Umansky V
    Clin Cancer Res; 2015 Dec; 21(24):5453-9. PubMed ID: 26289067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights.
    Faje A
    Pituitary; 2016 Feb; 19(1):82-92. PubMed ID: 26186958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ipilimumab-associated colitis or refractory Clostridium difficile infection?
    Gupta A; Khanna S
    BMJ Case Rep; 2015 Jul; 2015():. PubMed ID: 26153295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correction to Lancet Oncol 2015; 16: 522-30. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
    Eggermont AM; Chiarion-Sileni V; Grob JJ
    Lancet Oncol; 2015 Jun; 16(6):e262. PubMed ID: 26065611
    [No Abstract]   [Full Text] [Related]  

  • 8. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients.
    Ferrucci PF; Gandini S; Battaglia A; Alfieri S; Di Giacomo AM; Giannarelli D; Cappellini GC; De Galitiis F; Marchetti P; Amato G; Lazzeri A; Pala L; Cocorocchio E; Martinoli C
    Br J Cancer; 2015 Jun; 112(12):1904-10. PubMed ID: 26010413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint blockade in patients with melanoma metastatic to the brain.
    Di Giacomo AM; Margolin K
    Semin Oncol; 2015 Jun; 42(3):459-65. PubMed ID: 25965364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ipilimumab-induced colitis in patients with metastatic melanoma.
    De Felice KM; Gupta A; Rakshit S; Khanna S; Kottschade LA; Finnes HD; Papadakis KA; Loftus EV; Raffals LE; Markovic SN
    Melanoma Res; 2015 Aug; 25(4):321-7. PubMed ID: 25933207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-testis antigens and immunotherapy in the light of cancer complexity.
    Grizzi F; Mirandola L; Qehajaj D; Cobos E; Figueroa JA; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):143-53. PubMed ID: 25901859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When are signal transduction targeted therapies acting as immunotherapy?
    Flaherty KT
    Cancer Biol Ther; 2015; 16(5):645-7. PubMed ID: 25807058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ipilimumab may increase the severity of cutenaous toxicity related to radiotherapy.
    Eryılmaz MK; Mutlu H; Salim DK; Musri FY; Tural D; Başsorgun I; Coşkun HŞ
    J Oncol Pharm Pract; 2016 Jun; 22(3):533-6. PubMed ID: 25694346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic therapy of metastatic melanoma: on the road to cure.
    Bhatia S; Tykodi SS; Lee SM; Thompson JA
    Oncology (Williston Park); 2015 Feb; 29(2):126-35. PubMed ID: 25683834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience.
    Gao J; He Q; Subudhi S; Aparicio A; Zurita-Saavedra A; Lee DH; Jimenez C; Suarez-Almazor M; Sharma P
    Oncogene; 2015 Oct; 34(43):5411-7. PubMed ID: 25659583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CTLA-4 therapy may have mechanisms similar to those occurring in inherited human CTLA4 haploinsufficiency.
    Bakacs T; Mehrishi JN
    Immunobiology; 2015 May; 220(5):624-5. PubMed ID: 25638260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Systemic treatment of distant metastatic malignant melanoma].
    Dabrowski E; Dippel E
    Radiologe; 2015 Feb; 55(2):99-100, 102-4. PubMed ID: 25609506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-lasting responses under treatment with ipilimumab: an argument against maintenance therapy?
    Dick J; Enk A; Hassel JC
    Dermatology; 2015; 230(1):8-10. PubMed ID: 25531526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapeutic management of metastatic, castration-resistant prostate cancer in the elderly: focus on non-chemotherapy agents.
    Graff JN; Beer TM
    Drugs Aging; 2014 Dec; 31(12):873-82. PubMed ID: 25387443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ipilimumab and whole brain radiation therapy for melanoma brain metastases.
    Gerber NK; Young RJ; Barker CA; Wolchok JD; Chan TA; Yamada Y; Friguglietti L; Beal K
    J Neurooncol; 2015 Jan; 121(1):159-65. PubMed ID: 25273687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.